Clinical Trial Update: A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) [Phase 1]

View source ↗

Summary

Completion of a Phase 1 study evaluating MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer’s disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• MK-2214

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED